Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
09 janv. 2024 08h00 HE
|
Cogent Biosciences, Inc.
Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; present results from complete SUMMIT Part 1 at 2024 AAAAI annual conference in...
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 08h00 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
11 déc. 2023 07h55 HE
|
Cogent Biosciences, Inc.
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose Nearly all patients achieved at...
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
09 déc. 2023 13h30 HE
|
Cogent Biosciences, Inc.
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated...
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
07 déc. 2023 09h00 HE
|
Cogent Biosciences, Inc.
Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently...
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
04 déc. 2023 08h00 HE
|
Cogent Biosciences, Inc.
- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional clinical data update from APEX Part 1 in patients with Advanced...
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
29 nov. 2023 08h00 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
02 nov. 2023 09h00 HE
|
Cogent Biosciences, Inc.
SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation SUMMIT Part I completed upsized enrollment during Q3; SUMMIT Part 2...
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
14 oct. 2023 12h30 HE
|
Cogent Biosciences, Inc.
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and...
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
08 août 2023 08h00 HE
|
Cogent Biosciences, Inc.
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023 Enrollment for Phase 3 PEAK trial in GIST continues on...